REPLACEMENT THERAPY FOR HEREDITARY ALPHA(1)-ANTITRYPSIN DEFICIENCY - A PROGRAM FOR LONG-TERM ADMINISTRATION

This retrospective chart review describes the efficacy and safety of long-term administration of intravenous alpha(1)-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 of 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three patients had self-limited adverse reactions to the AAT with one patient requiring a brief hospitalization.